Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Authors:
Open Access
- 10 August 2017
- journal article
- case report
- Published by Springer Nature in British Journal of Cancer
- Vol. 117 (7) , 921-924
Abstract
Background: Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. Methods: In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids. Results: This report describes the only case of immune-mediated myocarditis treated with ATGAM resulting in a favourable outcome. Conclusions: Use of ATGAM should be considered in cases of steroid-refractory immune-mediated myocarditis and administered in close consultation with a cardiac transplant team experienced in the use of this agent.Keywords
This publication has 16 references indexed in Scilit:
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyJournal for ImmunoTherapy of Cancer, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapyBMJ Case Reports, 2015
- Managing Immune Checkpoint-Blocking Antibody Side EffectsAmerican Society of Clinical Oncology Educational Book, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill PatientAnnals of Pharmacotherapy, 2014
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin TherapyJournal of Clinical Oncology, 2011